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Nontuberculous mycobacteria (NTM) are ubiquitous organisms that are increa-
singly recognized as important causes of chronic pulmonary infection in non-
immunocompromised individuals.
1 Mycobacterium avium complex (MAC) and
Mycobacterium abscessus constitute the most commonly encountered causes of
NTM lung disease in Korea,
2 and several other NTM have been identified as
pathogens.
3,4
Mycobacterium celatum was first described in 1993 as a new species with a
mycolic acid pattern that closely resembled  Mycobacterium xenopi (xenopi-like),
although it was biochemically indistinguishable from MAC.
5 M. celatum is an
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Mycobacterium celatum is a nontuberculous mycobacterium that rarely causes
pulmonary disease in immunocompetent subjects. We describe the successful
treatment of M. celatum lung disease with antimicobacterial chemotherapy and
combined pulmonary resection. A 33-year-old woman was referred to our hospital
with a 3-month history of a productive cough. Her medical history included
pulmonary tuberculosis 14 years earlier. Her chest X-ray revealed a large cavitary
lesion in the left upper lobe. The sputum smear was positive for acid-fast bacilli,
and M. celatum was subsequently identified in more than three sputum cultures,
using molecular methods. After 1 year of therapy with clarithromycin, ethambutol,
and ciprofloxacin, the patient underwent a pulmonary resection for a persistent
cavitary lesion. The patient was considered cured after receiving 12 months of
postoperative antimycobacterial chemotherapy. There has been no recurrence of
disease for 18 months after treatment completion. In summary, M. celatum is an
infrequent cause of potentially treatable pulmonary disease in immunocompetent
subjects. Patients with M. celatum pulmonary disease who can tolerate resectional
surgery might be considered for surgery, especially in cases of persistent cavitary
lesions despite antimycobacterial chemotherapy.
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INTRODUCTIONuncommon cause of human infection, with an invasive
disease occurring primarily in the form of acquired immuno-
deficiency syndrome (AIDS) patients.
6 There are only a
few case reports of M. celatum lung disease in immuno-
competent patients.
7-9 To date, only one case of M. celatum
lung disease has been reported in Korea.
10 However, this
patient was given first-line anti-tuberculosis drugs and the
treatment outcome is unknown. 
We report an immunocompetent adult patient with M.
celatum lung disease who was successfully treated with a
pulmonary resection in combination with antimycobacterial
chemotherapy with clarithromycin, ethambutol, and cipro-
floxacin.
A 35-year-old woman was referred to our hospital for fur-
ther examination and management of probable NTM lung
disease. The patient’s medical history included a pulmo-
nary tuberculosis episode when she was 21 years old. She
lived in an urban area and had no history of smoking,
alcoholism, or use of immunosuppressive drugs. 
Four months before her visit to our hospital, the patient
reported a three-month history of a productive cough. A
chest radiograph revealed a large cavity in the left upper
lobe. The patient was initially diagnosed with pulmonary
tuberculosis and received isoniazid, rifampin, ethambutol,
and pyrazinamide. Two months later, NTM were cultured
from her sputum, and the colonies were identified as M.
celatum. She was referred to our hospital for probable NTM
lung disease.
Physical examination upon presentation showed that the
patient was 162 cm tall and weighed 44 kg. The results of
the clinical laboratory tests were unremarkable, apart from
a moderately elevated erythrocyte sedimentation rate (69
mm/hr) and C-reactive protein (0.69 mg/dL). A human im-
munodeficiency virus antibody test was negative. A chest
radiography revealed a large cavitary lesion in the left upper
lobe and multiple nodular opacities that involved the right
lung (Fig. 1A), which appeared to improve slightly after 4
months of treatment with anti-tuberculosis drugs. Her
sputum was positive in acid-fast bacilli (AFB) staining,
and numerous mycobacterial colonies were cultured from
three sputum specimens at our hospital. All of these
colonies were subsequently identified as M. celatum. This
identification was confirmed using a polymerase chain
reaction (PCR)-restriction fragment length polymorphism
method, based on the rpoB gene.
11 Although the patient
was recommended for a further work-up and a change of
drug regimen, she was lost from follow-up.
Twenty-two months later, the patient revisited our hospi-
tal due to a persistent productive cough. A chest radiogra-
phy showed aggravation of the cavitation in the left upper
lobe, as well as enlargement of the nodular lesions in the
right lung (Fig. 1B). The smears of two sputum specimens
were positive for AFB, and yielded M. celatum. Antimi-
crobial susceptibility testing was performed at the Korean
Institute of Tuberculosis. The isolate was found to be
susceptible to clarithromycin [minimal inhibition concen-
tration (MIC), 1 µg/mL] and ciprofloxacin (MIC, 0.25
µg/mL) using the broth microdilution method according to
the guidelines set forth by the National Committee for
Clinical Laboratory Standards (NCCLS).
12 In addition,
using the absolute concentration method on the Lowenstein-
Jensen medium, the isolate was shown to be susceptible to
ethambutol (critical concentration, 2 µg/mL), streptomycin
(critical concentration, 10 µg/mL), and kanamycin (critical
concentration, 40 µg/mL), but resistant to isoniazid (critical
concentration, 0.2 µg/mL) and rifampin (critical concentra-
tion, 40 µg/mL). Combination antimycobacterial chemo-
therapy, which included clarithromycin (1,000 mg/day),
ethambutol (800 mg/day), and ciprofloxacin (1,000
mg/day), was initiated. Conversion to negative sputum cul-
tures was achieved in 3 months. 
Despite 12 months of antimycobacterial chemotherapy,
the patient suffered from persistent sputum production. A
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Fig. 1.A 35 year-old woman with Mycobacterium celatumlung disease. (A) The
posteroanterior chest radiography at first visit shows a large cavitary lesion in
the left upper lobe. Note the multiple nodular opacities involving the right lung.
(B) The chest radiography at the subsequent revisit shows aggravation of the
cavitation in the left upper lobe, as well as enlargement of the nodular lesions in
the right lung. (C) The chest radiography taken after 12 months of antibiotic
treatment shows that the size of the cavitary lesion in the left upper lobe is
unchanged, although the multiple nodular lesions in the right lung have
improved. (D) The chest computed tomography scan taken after 12 months of
antibiotic treatment reveals a large remnant cavitary lesion that involves both
the left upper lobe and the superior segment of the left lower lobe. 
A
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Dchest radiography revealed that the size of the cavitary
lesion in the left upper lobe was unchanged, although the
multiple nodular lesions in the right lung had improved
(Fig. 1C). Chest computed tomography revealed a large
remnant cavitary lesion that involved both the left upper
lobe and the superior segment of the left lower lobe (Fig.
1D). This cavitary lesion was considered to have a high
possibility of relapse. Therefore, the patient underwent a
left upper lobectomy and superior segmentectomy of the
left lower lobe. The microscopic findings were parenchy-
mal destruction with cavity and chronic granulomatous
inflammation with caseous necrosis. The tissue culture was
not requested during the surgery. The patient was consider-
ed cured after receiving 12 months of postoperative anti-
mycobacterial chemotherapy. There has been no recurrence
of disease 18 months after treatment completion.
To the best of our knowledge, this is the first case of M.
celatum lung disease being successfully treated with
antimycobacterial chemotherapy in combination with pul-
monary resection in Korea. In this case, M. celatum was
clearly shown to be the etiologic agent of the cavitary
lesion of the left lung. Considering the clinical and radio-
graphic features, in addition to the repeated isolation of M.
celatum, the diagnostic criteria for NTM lung disease were
fulfilled.
1
The clinical outcome for many M. celatum-infected
patients is poor, probably due to their profound immuno-
suppression. The previously reported immunocompetent
patients with pulmonary infection were assigned different
treatment regimens with combinations of antimycobac-
terial agents, mainly ethambutol and clarithromycin.
7-9
Clinical improvement was obtained within 6 months of the
initiation of therapy in two out of three patients. One pati-
ent who received anti-mycobacterial therapy died 6 weeks
after starting therapy from complications that were appa-
rently related to the M. celatum infection.
7 
The susceptibility test profiles of the previously reported
cases showed variability.
5-9 The organism was generally
found to be susceptible to clarithromycin and ciprofloxa-
cin, with ciprofloxacin resistance being reported infrequen-
tly.
13-15 All the reported isolates were resistant to rifampin
and most were resistant to isoniazid. In an animal model of
M. celatum infection, clarithromycin, azithromycin, and
ethambutol were shown to be the most active agents.
16
Susceptibility testing is advisable in order to guide treat-
ment choices. Based on the recommended treatment regi-
mens and the results of in vitro susceptibility testing, we
selected a combination of ethambutol, clarithromycin, and
ciprofloxacin for our patient. However, organisms such as
M. celatum have limited in vitro susceptibility, with limited
evidence for a correlation between in vitro susceptibility
and clinical response in the treatment of M. celatum pul-
monary disease.
1
In summary, M. celatum is an infrequent cause of poten-
tially treatable pulmonary disease in immunocompetent
subjects. Patients with M. celatum lung disease who can
tolerate resectional surgery might be considered for sur-
gery, especially in cases of persistent cavitary lesions des-
pite antimycobacterial chemotherapy. 
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